Halozyme Therapeutics (HALO) Tops Q1 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Wall St set for lower open as AI jitters rekindle, oil gains
- Oil jumps on escalating Middle East conflict
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- JPMorgan says AI stock selling may be nearing its limit as positioning resets
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $124.83 --0%
Revenue Growth %: +37.6%
Financial Fact:
Selling, general and administrative: 11.6M
Today's EPS Names:
SICP, MNSB, CFFI, More
Revenue Growth %: +37.6%
Financial Fact:
Selling, general and administrative: 11.6M
Today's EPS Names:
SICP, MNSB, CFFI, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q1 EPS of $1.60, $0.06 better than the analyst estimate of $1.54. Revenue for the quarter came in at $377 million versus the consensus estimate of $358.45 million.
GUIDANCE:
Halozyme Therapeutics sees FY2026 EPS of $7.75-$8.25, versus the consensus of $8.09. Halozyme Therapeutics sees FY2026 revenue of $1.71-1.81 billion, versus the consensus of $1.76 billion.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SK Hynix could join the Nasdaq 100 if it expands its ADR float: Goldman
- Pool Corp. (POOL) Tops Q3 EPS by 4c; offers guidance
- Badger Meter (BMI) Tops Q3 EPS by 1c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
